Microphysiological system to advance adoptive cell therapy
Adoptive cell therapy has emerged as promising cancer treatment in recent years. For reducing the challenges such treatments face, a novel microfluidic platform, developed by the group of Andreas Hierlemann in collaboration with members from Timm Schroeder’s group, helps to improve the process of identifying potent anti-tumour immune cells and their corresponding targets, bridging the gap between in-vitro and in-vivo studies. This platform introduces a simple and user-friendly immunocompetent microphysiological systems (iMPS) that offers: (i) long-term triple culture of cells with anti-tumor NK cells, (ii) microscopy-based observation of direct NK cell interaction and evaluation of the spontaneous beating activity of cardiac microtissues (CarMTs), (iii) collection of the cell-culture supernatant for chemokine/cytokine profiling, and (iv) harvesting of all tissue models for endpoint analyses. This research work is aimed at demonstrating the potential and versatility of iMPSs for use in immuno-oncology research, especially for early in-vitro validation and safety assessment of therapy approaches.
ارسال به دوستان